Skip to main content
. Author manuscript; available in PMC: 2015 Nov 28.
Published in final edited form as: J Control Release. 2014 Sep 7;194:197–210. doi: 10.1016/j.jconrel.2014.08.030

Figure 1.

Figure 1

Scheme of the antibody-based targeting strategy for selective delivery of PTD-modified toxins to tumor cells. When antibody-heparin conjugate and PTD-modified toxin are mixed together, they automatically form a strong yet reversible complex via electrostatic interaction between anionic heparin and cationic PTD. Following administration to the blood circulation, the complexes are targeted to tumor mediated by the antibody that specifically binds to antigens overexpressed on the tumor cells. Once targeted, slowly released PTD-modified toxins from the antibody-heparin conjugate counterpart internalizes into tumor cells via PTD-mediated transduction, which eventually results in apoptosis of the tumor cells.